Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: PATHOLOGIC COMPLETE RESPONSE, . Treffer: 13
2022
Terbuch, A; Absenger, G
Neoadjuvant treatment in non-small-cell lung cancer-the earlier, the better
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00828-3
Web of Science
FullText
FullText_MUG
2021
Bartsch, R; Singer, CF; Pfeiler, G; Hubalek, M; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Muy-Kheng, TM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Br J Cancer. 2021; 124(11): 1795-1802.
Doi: 10.1038/s41416-021-01284-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Hecht, M; Gostian, AO; Eckstein, M; Rutzner, S; von, der, Grün, J; Illmer, T; Hautmann, MG; Klautke, G; Laban, S; Brunner, T; Hinke, A; Becker, I; Frey, B; Semrau, S; Geppert, CI; Hartmann, A; Balermpas, P; Budach, W; Gaipl, US; Iro, H; Fietkau, R
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.
J Immunother Cancer. 2020; 8(2):
Doi: 10.1136/jitc-2020-001378
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hurvitz, SA; Martin, M; Press, MF; Chan, D; Fernandez-Abad, M; Petru, E; Rostorfer, R; Guarneri, V; Huang, CS; Barriga, S; Wijayawardana, S; Brahmachary, M; Ebert, PJ; Hossain, A; Liu, J; Abel, A; Aggarwal, A; Jansen, VM; Slamon, DJ
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
CLIN CANCER RES. 2020; 26(3): 566-580.
Doi: 10.1158/1078-0432.CCR-19-1425
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Fokas, E; Allgäuer, M; Polat, B; Klautke, G; Grabenbauer, GG; Fietkau, R; Kuhnt, T; Staib, L; Brunner, T; Grosu, AL; Schmiegel, W; Jacobasch, L; Weitz, J; Folprecht, G; Schlenska-Lange, A; Flentje, M; Germer, CT; Grützmann, R; Schwarzbach, M; Paolucci, V; Bechstein, WO; Friede, T; Ghadimi, M; Hofheinz, RD; Rödel, C, , German, Rectal, Cancer, Study, Group
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
J Clin Oncol. 2019; 37(34): 3212-3222.
Doi: 10.1200/JCO.19.00308
PubMed
FullText
FullText_MUG
2018
Kühn, T; Classe, JM; Gentilini, OD; Tinterri, C; Peintinger, F; de Boniface, J
Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting.
Breast Care (Basel). 2018; 13(5):337-341
Doi: 10.1159/000492437
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Moinfar, F; Gruber, C; Petru, E; Bartsch, R; Tendl, KA; Fuchs, D; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M; Austrian Breast and Colorectal Cancer Study Group
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Clin Cancer Res. 2017; 23(14):3676-3683
Doi: 10.1158/1078-0432.CCR-16-2373
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Bossuyt, V; Provenzano, E; Symmans, WF; Boughey, JC; Coles, C; Curigliano, G; Dixon, JM; Esserman, LJ; Fastner, G; Kuehn, T; Peintinger, F; von Minckwitz, G; White, J; Yang, W; Badve, S; Denkert, C; MacGrogan, G; Penault-Llorca, F; Viale, G; Cameron, D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
ANN ONCOL. 2015; 26(7): 1280-1291.
Doi: 10.1093/annonc/mdv161
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2014
Steger, GG; Greil, R; Lang, A; Rudas, M; Fitzal, F; Mlineritsch, B; Hartmann, BL; Bartsch, R; Melbinger, E; Hubalek, M; Stoeger, H; Dubsky, P; Ressler, S; Petzer, AL; Singer, CF; Muss, C; Jakesz, R; Gampenrieder, SP; Zielinski, CC; Fesl, C; Gnant, M
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
ANN ONCOL. 2014; 25(2): 366-371.
Doi: 10.1093/annonc/mdt508
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2009
Tinkl, D; Grabenbauer, GG; Golcher, H; Meyer, T; Papadopoulos, T; Hohenberger, W; Sauer, R; Brunner, TB
Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
Strahlenther Onkol. 2009; 185(9):557-66
Doi: 10.1007/s00066-009-1977-9
Web of Science
PubMed
FullText
FullText_MUG
2007
Steger, GG; Galid, A; Gnant, M; Mlineritsch, B; Lang, A; Tausch, C; Rudas, M; Greil, R; Wenzel, C; Singer, CF; Haid, A; Postlberger, S; Samonigg, H; Luschin-Ebengreuth, G; Kwasny, W; Klug, E; Kubista, E; Menzel, C; Jakesz, R
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
J Clin Oncol. 2007; 25(15):2012-2018
Doi: 10.1200/JCO.2006.09.1777
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2006
Peintinger, F; Symmans, WF; Gonzalez-Angulo, AM; Boughey, JC; Buzdar, AU; Yu, TK; Hunt, KK; Singletary, SE; Babiera, GV; Lucci, A; Meric-Bernstam, F; Kuerer, HM
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
Cancer. 2006; 107(6): 1248-1254.
Doi: 10.1002/cncr.22111
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2003
Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
J Clin Oncol. 2003; 21(9):1752-1759
Doi: 10.1200/JCO.2003.11.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG